Opinion|Videos|October 25, 2024
LEAP-012 Study Results
Panelists discuss the results of the LEAP-012 study, highlighting the efficacy of transarterial chemoembolization combined with lenvatinib and pembrolizumab in patients with intermediate-stage hepatocellular carcinoma and Child-Pugh class A disease.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Dr Li: Please discuss the findings from the LEAP-012 study in patients with Child-Pugh class A disease.
Advertisement
Related to this article
Lyudmila Bazhenova, MD, FASCO, outlines key considerations for treatment intensification in EGFR-mutated NSCLC.
Five Huntsman Cancer Institute at the University of Utah colleagues earned endowed chair appointments, including new appointments.
The CHMP recommended EU approval of T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer,
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The CHMP has recommended the approval of sacituzumab govitecan/pembrolizumab for treatment-naive, PD-L1-positive metastatic TNBC in the European Union.
Overall survival was the sole US primary end point of the phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab and was not met.
Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
Teclistamab plus talquetamab met the primary PFS end point and improved overall survival in relapsed/refractory multiple myeloma in MonumenTAL-6.
Advertisement
Advertisement
Trending on OncLive
1
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
2
Breast Cancer Buzz at ASCO 2026: De-Escalation Strategies, Targeted Therapies, and More
3
Epcoritamab Misses Sole US Primary End Point of Overall Survival in R/R DLBCL
4
Dr Lee on the Optimal Duration of Adjuvant Osimertinib in EGFR+ NSCLC
5